Edwards Lifesciences reported double-digit revenue growth in the second quarter and lifted the bottom end of its guidance. The stock was up 3.9% to $83.82 after the bell. A lymphoma drug co-developed ...

The chip makers are best known for competing in the GPU business, but they’re stepping up their offerings in the attractive market for server CPUs.

Lyntris is backed by private-equity firm Trive Capital. "Thrive Capital-Backed Lyntris Files for IPO," at 5:51 p.m. ET, incorrectly said the company is backed by Thrive Capital. It also incorrectly ...

Shares of Amkor Technology were rising after hours after the company announced a strategic partnership with Nvidia to develop semiconductor packaging and test technologies fit for next-generation ...

Ocean Power Technologies acquired strategic subsea development technology assets from Columbia Power Technologies. Ocean Power, a renewable-powered marine systems company, said Thursday the purchase ...

President Donald Trump and U.S. Trade Representative Jamieson Greer are making a fresh move with tariffs on Thursday.

MacroGenics made progress in an ongoing Phase 1 study for a drug aimed at treating advanced tumors, reporting it has moved a certain patient cohort to a second stage of the study's design.

EnerSys said it was awarded a revised grant from the U.S. Energy Department of $150 million for the development of its lithium cell manufacturing facility in Greenville, South Carolina.

GE HealthCare Technologies said James Saccaro, the company's chief financial officer, will step down and take a role outside of the medical technology industry. His last day with the company will be ...

Oklo received startup authorization from the U.S. Department of Energy for its Groves Isotope Test Reactor.

"Genco's advisors have engaged with Diana's advisors on multiple occasions in recent weeks to discuss the price, terms and structure of Diana's proposal and to assess whether a transaction that fully ...

A drug co-developed by Genmab and AbbVie to treat a certain type of lymphoma failed to meet its primary endpoint in a Phase 3 trial. The companies on Thursday clarified that the trial's sole U.S.